Recursive, an AI startup founded last year, is starting to live up to its name. The company, which is trying to build AI that can improve itself, released its first model, Flint, on Wednesday. Flint ...
For the past few days I’ve been testing an impressive open-weight AI coding model called Flint. It suggests that fully recursive self-improvement, or RSI—an exciting and controversial approach that ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Regan Peng is an AI founder and former senior tech executive, focused on personal AI, ...
“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...
Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.
On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...
Anthropic reveals that Claude now writes over 80% of its production code, with engineers shipping 8x more code per quarter than in 2024. The company’s new Anthropic Institute paper maps the path to ...
RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...
Recursion Pharmaceuticals is using AI to improve how we develop drugs. The company has partnered with several major corporations in this quest. The biotech has yet to show meaningful results from its ...